Definium Therapeutics (DFTX) CFO Brandi Roberts Sells 3,377 Shares

What Happened
Brandi Roberts, Chief Financial Officer of Definium Therapeutics (DFTX), sold 3,377 common shares on September 25, 2026 for a total of approximately $123,497 (weighted average price $36.57). The sale is reported as a disposition (S) and was done to satisfy tax withholding obligations in connection with the settlement of vested restricted stock units.

Key Details

• Transaction date: September 25, 2026. Form 4 filed September 29, 2026 (filed four days after the sale; appears later than the typical 2-business-day reporting window).
• Shares sold: 3,377; weighted-average price reported $36.57; total proceeds ≈ $123,497.
• Price range: sales occurred at prices between $36.24 and $36.98 (per footnote); the $36.57 is a weighted average.
• Reason/footnotes: Sold to satisfy withholding taxes on vested RSUs pursuant to a sell-to-cover election under a Rule 10b5-1 plan adopted May 30, 2025 (Footnote F1). Footnote F2 notes multiple trades and offers to provide per-price breakdown on request.
• Shares owned after transaction: not disclosed in this filing.

Context
This was a sell-to-cover tax withholding sale tied to RSU vesting (common executive practice) rather than a discretionary open-market sale intended to express a view on the company. Such tax-related disposals are generally considered routine and are less informative about insider sentiment than purchases.